ASH 2015 | Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL
Peter Hillmen
• 4 Dec 2015
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, explains how Bruton’s tyrosine kinase inhibitors, like ibrutinib and acalabrutinib (ACP-196), target chronic lymphocytic leukemia (CLL) cells and the common side-effects experienced by these drugs.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
